Procaterol

• UNSPSC Description:

  Procaterol is an oral selective β2 adrenergic receptor agonist. Procaterol inhibits eosinophil migration and the release of eosinophil chemotactic factor from BEAS-2B cells through a cyclic AMP-dependent mechanism. Procaterol has a large dose difference existing between the bronchodilator effect and the anabolic effect in rat, can be used for asthma research in athletes[1].

• Target Antigen:

  Adrenergic Receptor

• Type:

  Reference compound

• Related Pathways:

  GPCR/G Protein;Neuronal Signaling

• Applications:

  Neuroscience-Neuromodulation

• Field of Research:

  Others

• Assay Protocol:

  https://www.medchemexpress.com/procaterol.html

• Solubility:

  10 mM in DMSO

• Smiles:

  O[C@@H](C(C=C1)=C(C=CC2=O)C(N2)=C1O)[C@@H](CC)NC(C)C

• Molecular Weight:

  290.36

• References & Citations:

  [1]Ikezono K, et al. Bronchodilating effect and anabolic effect of inhaled procaterol. Int J Sports Med. 2008 Nov;29(11):888-94. |[2]Tashimo H, et al. Effect of procaterol, a beta(2) selective adrenergic receptor agonist, on airway inflammation and hyperresponsiveness. Allergol Int. 2007 Sep;56(3):241-7. |[3]Koyama S, et al. Procaterol inhibits IL-1beta- and TNF-alpha-mediated epithelial cell eosinophil chemotactic activity. Eur Respir J. 1999 Oct;14(4):767-75. |[4]Yamaya M, et al. Procaterol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Eur J Pharmacol. 2011 Jan 10;650(1):431-44. |[5]Komatani-Tamiya N, et al. Procaterol-stimulated increases in ciliary bend amplitude and ciliary beat frequency in mouse bronchioles. Cell Physiol Biochem. 2012;29(3-4):511-22.

• Shipping Conditions:

  Room temperature

• Clinical Information:

  Phase 4

• CAS Number:

  72332-33-3